| Literature DB >> 32375039 |
Artem Babaian1, Katharina Rothe2, Dylan Girodat3, Igor Minia4, Sara Djondovic5, Miha Milek4, Sandra E Spencer Miko6, Hans-Joachim Wieden3, Markus Landthaler7, Gregg B Morin8, Dixie L Mager2.
Abstract
The ribosome is an RNA-protein complex that is essential for translation in all domains of life. The structural and catalytic core of the ribosome is its ribosomal RNA (rRNA). While mutations in ribosomal protein (RP) genes are known drivers of oncogenesis, oncogenic rRNA variants have remained elusive. We identify a cancer-specific single-nucleotide variation in 18S rRNA at nucleotide 1248.U in up to 45.9% of patients with colorectal carcinoma (CRC) and present across >22 cancer types. This is the site of a unique hyper-modified base, 1-methyl-3-α-amino-α-carboxyl-propyl pseudouridine (m1acp3Ψ), a >1-billion-years-conserved RNA modification at the peptidyl decoding site of the ribosome. A subset of CRC tumors we call hypo-m1acp3Ψ shows sub-stoichiometric m1acp3Ψ modification, unlike normal control tissues. An m1acp3Ψ knockout model and hypo-m1acp3Ψ patient tumors share a translational signature characterized by highly abundant ribosomal proteins. Thus, m1acp3Ψ-deficient rRNA forms an uncharacterized class of "onco-ribosome" which may serve as a chemotherapeutic target for treating cancer patients.Entities:
Keywords: RNA modification; cancer; colorectal carcinoma; diffuse large B-cell lymphoma; onco-ribosome; rRNA variation; ribosomal RNA; ribosomal heterogeneity; ribosome
Mesh:
Substances:
Year: 2020 PMID: 32375039 DOI: 10.1016/j.celrep.2020.107611
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423